Cash figures as of 2026-05-26. Database snapshot: 2026-09-21.
Price history
Loading NBTX daily closes…
Loading price history…
Pipeline assets
NBTXR3
Stage not disclosed · Active
Aliases JNJ-1900
Partnerships Janssen Pharmaceutica NV (license agreement July 2023; worldwide development/commercialization)
Indications
Head and neck cancer(Stage not disclosed)
Status note 20-F: 'NBTXR3, which is referred to as JNJ-1900 by Janssen Pharmaceutica NV, refer to the same product candidate.' Radioenhancer; Janssen conducts JNJ-1900 development/commercialization worldwide per license agreement.
Per-asset detail extracted from the 20-F filed 2026-03-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.